Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon α 2B, doxorubicin, and 5-fluorouracil -: A communication

被引：20

作者：

Patt, YZ

Hoque, A

Roh, M

Ellis, L

Lozano, R

Carrasco, CH

Charnsangavej, C

Cleary, K

机构：

[1] Allegheny Gen Hosp, Dept Gastrointestinal Med Oncol & Digest Dis, Div Med, Pittsburgh, PA 15212 USA

[2] Allegheny Gen Hosp, Dept Surg Oncol, Div Surg, Pittsburgh, PA 15212 USA

[3] Allegheny Gen Hosp, Div Pharm, Pittsburgh, PA 15212 USA

[4] Allegheny Gen Hosp, Dept Diagnost Radiol, Div Diagnost Imaging, Pittsburgh, PA 15212 USA

[5] Allegheny Gen Hosp, Dept Pathol, Div Pathol, Pittsburgh, PA 15212 USA

[6] Allegheny Gen Hosp, Dept Surg Oncol, Pittsburgh, PA 15212 USA

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1999年 / 22卷 / 02期

关键词：

hepatocellular carcinoma; chemobiotherapy; platinol; recombinant interferon alpha 2b; doxorubicin; 5-fluorouracil; PIAF;

D O I：

10.1097/00000421-199904000-00024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The case described here illustrates the antitumor activity of a four-drug systemic combination chemobiotherapy with platinol, recombinant interferon alpha 2b, doxorubicin (Adriamycin), and 5-fluorouracil (5-FU) (PIAF) in a patient with diffuse hepatocellular carcinoma involving the liver and lungs.

引用

页码：209 / 213

页数：5

共 40 条

[1] PHARMACOKINETICS OF INTRA-ARTERIAL MITOMYCIN-C WITH OR WITHOUT DEGRADABLE STARCH MICROSPHERES (DSM) IN THE TREATMENT OF NON-RESECTABLE LIVER-CANCER [J].